Successful treatment for infected biloma after endoscopic ultrasound-guided hepaticogastrostomy using double stent placement technique

Takeshi Ogura, Atsushi Okuda, Akira Miyano, Nobu Nishioka, Kazuhide Higuchi

Second Department of Internal Medicine, Osaka Medical College, Osaka 569-8686, Japan.

Correspondence to: Dr. Takeshi Ogura, Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigakuchou, Takatsukishi, Osaka 569-8686, Japan. E-mail: oguratakeshi0411@yahoo.co.jp


Received: 24 Nov 2017  First Decision: 6 Mar 2018  Revised: 8 Mar 2018  Accepted: 29 Mar 2018  Published: 23 Apr 2018

Science Editor: Charles F. Bellows  Copy Editor: Jun-Yao Li  Production Editor: Huan-Liang Wu

Abstract
This case report describes a treatment of an elderly man who had undergone pancreaticoduodenectomy (Whipple Procedure) due to bile duct cancer. Herein, we describe technical tips of endoscopic ultrasound (EUS)-guided hepaticojejunostomy EUS-HJS combined with EUS-guided antegrade stenting (EUS-AS) using novel plastic stent. First, intrahepatic bile duct was punctured using 19G fine needle aspiration needle. Next, the 0.025-inch guidewire was inserted into the biliary tract. After the guidewire was advanced into the intestine, the bile duct and the intestine wall were dilated using by balloon catheter. The covered metal stent delivery system was antegradely inserted across the stricture site, and stent placement was performed from the intestine to the bile duct. Finally, stent placement from the intrahepatic bile duct to the intestine using novel plastic stent was successfully performed without any adverse events.

Keywords: Endoscopic ultrasound, endoscopic ultrasound-guided hepaticojejunostomy, liver abscess, endoscopic ultrasound-guided biliary drainage

INTRODUCTION
Trans-jejunum biliary drainage with endoscopic ultrasound (EUS)-guided hepaticojejunostomy (EUS-HJS) is now a well established procedure. However, EUS-guided biliary drainage (EUS-BD) procedures have possibility of several adverse events such as stent migration or bile leakage. To prevent these adverse events, a covered, self-expandable, metal stent (CSEMS) is usually selected and EUS-BD is sometimes combined with EUS-guided antegrade stenting (AS). If CSEMS obstruction occurs, re-intervention is challenging in
patients with a history of EUS-HJS because of limited lumen space compared with the stomach. Also, due to large diameter of EUS-HJS stent, bile juice reflux may cause vomiting. Recently, novel plastic stent has been introduced available in Japan. The plastic stent, which is a push-type stent and usually not possible to retract, has a total length of 20 cm, an effective length of 15 cm, and 4 flanges. The proximal end has a pigtail structure to prevent stent migration and the distal end is tapered. This plastic stent has clinical impact because it is able to prevent stent migration into the abdominal cavity. Although EUS-guided biliary drainage, such as hepaticogastrostomy (HGS), offers an alternative method to percutaneous transhepatic biliary drainage, various adverse events such as stent migration into the abdominal cavity are associated with EUS-HGS and considerable effort has been directed towards preventing them. Despite these efforts, adverse events such as infected biloma after EUS-HGS still arise due to frequent reflux cholangitis through EUS-HGS stent, or bile duct obstruction by a covered metal stent. A longer HGS stent may help to prevent reflux cholangitis, but if infected biloma occurs around an EUS-HGS, the stent must be exchanged. Other adverse events including liver abscess, may occur due to various reasons, and should be treated. Here, we describe treatment of a liver abscess around an EUS-HGS, using double stent placement stent in an elderly man who had a history of surgery for bile duct cancer.

CASE REPORT

A 78-year-old man who had undergone pancreaticoduodenectomy due to bile duct cancer 1 year previously, was admitted to our hospital with obstructive jaundice. A benign bile-jejunum anastomosis stricture was diagnosed with computed tomography. Because the patient declined to undergo percutaneous drainage, the doctor proposed an alternative EUS-HGS procedure. The procedure was performed using a 10 mm × 10 cm, Niti-S Biliary Covered Stent (partially-covered, TaeWoong Medical, Seoul, South Korea; Century Medical Inc., Tokyo, Japan) [Figure 1A]. This resolved the obstructive jaundice, no adverse events occurred, and the patient was discharged after 2 weeks.

Four weeks after the EUS-HGS procedure, the patient presented with a fever and elevated inflammatory indicators and was consequently readmitted to hospital. Computed tomography revealed a biloma around the EUS-HGS stent [Figure 1B]. This biloma was considered to be complicated with infection. Endoscopic treatment for infected biloma was attempted as follows. An endoscopic retrograde cholangiopancreatography (ERCP) catheter (MTW Endoskopie, Düsseldorf, Germany) was initially inserted into the biliary tract through the EUS-HGS stent. A 0.025-inch guidewire (VisiGlide; Olympus Medical Systems, Tokyo, Japan) was inserted into the catheter and the metal stent was removed through
The scope (JF 260V; Olympus Medical Systems, Tokyo, Japan). An additional ERCP catheter was inserted into the biliary tract, contrast medium was injected, and cholangiography visualized the infected biloma [Figure 2A]. Therefore, guidewires were inserted through the catheters in both the infected biloma and biliary tract [Figure 2B] so that a new EUS-HGS could be performed. A 7-Fr, double pig tail, 12-cm plastic stent (Medi-Globe GmbH; Achenmühle, Germany) was placed from the infected biloma to the stomach. Finally, a new, plastic stent placement (Type IT; Gadelius Medical Co, Ltd, Tokyo, Japan) was completed the EUS-HGS procedure [Figure 2C].

Thereafter, after 1 week, inflammatory indicators and clinical symptoms were immediately resolved and the patient was discharged. This stent was removed after 2 months, and recurrence of biloma was not seen.

**DISCUSSION**

Fully covered metal stents deployed via EUS-HGS offer several advantages. Bile leakage from the gap between a fully covered metal stent and a fistula created during EUS-HGS to insert various devices may be less likely. This type of stent also remains patent for longer periods than plastic stents\(^{[11]}\). In addition, a fully covered metal stent itself can confer a tamponed effect on bleeding from the stomach wall or vessels around the bile duct. The disadvantages of metal stents include high cost, potential for branch bile duct obstruction, and the possibility of shortening. Focal cholangitis due to branch bile duct obstruction by a covered metal stent deployed after EUS-HGS is an adverse event that can usually be conservatively treated\(^{[12]}\). However, a complicating, infected biloma is likely to require intervention. Kumata *et al.*\(^{[12]}\) described a hepatic abscess that developed within the cavity between the stomach and liver after EUS-HGS. A 15-mm, lumen-apposing metal stent was deployed because the abscess could be accessed from

---

Figure 2. (A) Contrast-enhanced cholangioscopy image shows infected biloma; (B) guidewire placed in liver abscess and biliary tract; (C) deployed double stent; (D) computed tomography image after this procedure.
the stomach and anchored by placing a plastic stent through it. The liver abscess in our patient was located in the hepatic parenchyma, which precluded the use of a lumen-apposing metal stent. Therefore, our technique is clinically useful for treating liver abscesses that arise after EUS-HGS, if percutaneous approach is refused by patients.

DECLARATIONS

Authors’ contributions
Manuscript writing: Ogura T
Interpretation of data for the work, revising it critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Ogura T, Okuda A, Miyano A, Nishioka N, Higuchi K

Financial support and sponsorship
None.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Patient consent
Obtained.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES